 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam Finds Partner for Cholesterol Program in The Medicines Company
February 07, 2013
Alnylam Finds Partner for Cholesterol Program in The Medicines Company
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
November 8, 2012 / Gene Silencing News - Alnylam Doses First Patients in Cholesterol Drug Trial
September 29, 2011 / Gene Silencing News - As Alnylam Files to Begin Testing Cholesterol Drug in Humans, Questions Linger Over Delivery Tech
July 14, 2011 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to UNC, Alnylam, FSU, and More
February 7, 2013 / Gene Silencing News - Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News